Consensus BioCryst Pharmaceuticals, Inc.

Stocks

BCRX

US09058V1035

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 31/10/2026 am IST			5-day change	1st Jan Change
8.470 ^USD	-0.59%		+10.72%	+8.59%

29/10	Biocryst Pharmaceuticals, Inc. Presents New Data for Orladeyo and Navenibart At the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting	CI
21/10	BioCryst Pharmaceuticals Pellet Form of Hereditary Angioedema Treatment Approved by US FDA	MT

Evolution of the Average Target: BioCryst Pharmaceuticals, Inc.

Evolution of the Target Price: BioCryst Pharmaceuticals, Inc.

Changes in Analyst Recommendations: BioCryst Pharmaceuticals, Inc.

26e51711730c7d84219b5c23.N4zVE_YCDuBZV773xj_-xpR8o5Yp2dLZkatrDcgZcsQ.f6GSVp0xbKQrPcqCtAi9pO0tkeQc7ISI_tMmepxtNosC6KUhslc2hzMCyQ~6bfa17cf50eb64a553379c2d6eeff50d

Analysts' recommendations: BioCryst Pharmaceuticals, Inc.

19/10	Wedbush Cuts Price Target on BioCryst Pharmaceuticals to $18 From $20, Keeps Outperform Rating	MT
10/09	RBC Downgrades BioCryst Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $11 From $13	MT
06/08	RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating	MT
05/08	Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating	MT
07/07	RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating	MT
07/04	RBC Capital Adjusts BioCryst Pharmaceuticals PT to $14 From $13, Maintains Outperform Rating	MT
25/03	BioCryst Shares Remain Undervalued, RBC Says	MT
27/02	Wedbush Adjusts Price Target on BioCryst Pharmaceuticals to $22 From $21, Maintains Outperform Rating	MT
30/01	RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Keeps Outperform Rating	MT
08/01	RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating	MT
30/12	BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says	MT
15/25/15	RBC Raises Price Target on BioCryst Pharmaceuticals to $15 From $14, Keeps Outperform Rating	MT
08/25/08	RBC Lifts Price Target on BioCryst Pharmaceuticals to $14 From $13, Keeps Outperform Rating	MT
01/25/01	Evercore ISI Downgrades BioCryst Pharmaceuticals to In Line From Outperform, Lifts Price Target to $8 From $12	MT
30/25/30	Wedbush Raises Price Target on BioCryst Pharmaceuticals to $18 From $16, Maintains Outperform Rating	MT
06/25/06	RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating	MT
25/25/25	RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating	MT
07/24/07	JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating	MT
18/23/18	BioCryst Pharmaceuticals Receives Upgrade From RBC to Outperform From Sector Perform, Price Target Raised to $10 From $9	MT
04/23/04	Jefferies Upgrades BioCryst Pharmaceuticals to Buy From Hold, Price Target is $11	MT
04/23/04	RBC Raises Price Target on BioCryst Pharmaceuticals to $9 From $8, Keeps Sector Perform, Speculative Risk	MT
13/23/13	BofA Securities Upgrades BioCryst Pharmaceuticals to Buy From Neutral, Price Target is $10	MT
07/23/07	RBC Trims BioCryst Pharmaceuticals' Price Target to $8 From $9, Keeps Sector Perform Speculative Risk Rating	MT
20/23/20	Evercore ISI Lowers Price Target on BioCryst Pharmaceuticals to $10 From $13, Maintains Outperform Rating	MT
06/23/06	RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $9 From $10, Maintains Sector Perform - Speculative Risk Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BIOCRYST PHARMACEUTICALS, INC.					+142.57%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.41%
	IQVIA HOLDINGS INC.					+15.87%
	BEONE MEDICINES AG					+17.86%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+40.24%
	Weighted average by Cap.					+27.64%